



March 1, 2022

Agenda

- NHSN Data: What can it do
- COVID Update
- Case Discussion

Washington DOH – Call for Hospitals reporting to NHSN

- Forum for DOH to share NHSN hospital AU reporting
- Allow antibiotic stewards to present and discuss how they use NHSN AU module for stewardship
- Identify successful approaches for reporting and validation




Marisa D'Angeli, MD, MPH
Kelly Kauber, MPH

NHSN AU Module

- To facilitate risk-adjusted inter and intra-facility AU benchmarking and evaluate AU trends over time for facility and for nation
- Introduced in 2015, updated in 2018
- Standardized method to show and compare AU in hospitals
- Tracks DOT
 - For categories of antimicrobial agents or for all antimicrobials
 - By unit or for the entire facility
- Can produce SAAR or rates



Tracking Hospital Acquired Infection: The Goal is Zero



Tracking Antimicrobial Use: How low can you go?

Who's setting the bar?



Is the bar appropriate?
That's not fair! I'm 6'5" and he's 4'2"

SAAR is the Bar:

Standardized Antimicrobial Administration Ratio

- **WHO:** Created by the CDC as a standard way to compare antimicrobial use within and between facilities
- **WHAT:** Ratio of observed antibiotic use versus Predicted antibiotic use
- **WHERE:** "Predicted antibiotic use" comes from hospitals who submitted data in 2017 to NHSN, ~6% of them were CAH.

Circumstances under which NHSN cannot generate SAAR values: long-term acute care (LTAC), orthopedic, psychiatric, or rehabilitation hospital. Pediatric and neonatal CAH populations

- **WHEN:** Current SAAR uses 2017 data
- **WHY:** To help facilities benchmark and identify opportunities for improvement



Tracking Antimicrobial Use: Is harder than it looks

Who: CDC

I will adjust this bar height based on the players involved and math*

SAAR is the Bar

The SAAR can't be zero

*Math

- Patient care location
- Facility type
- Teaching status
- Bed size
- Number/proportion ICU beds
- Length of stay

SAAR = Standardized Antimicrobial Administration Ratio



	Hospitals in Adult and/or Pediatric SAAR Referent Population ^a (n = 457)	Hospitals Reporting ≥1 Month of AU Option Data From SAAR-Eligible Location ^b (n = 1511)	Hospitals Enrolled in NHSN With ≥1 Active SAAR-Eligible Location ^c (n = 4668)
Facility type, no. hospitals (%)			
General acute care	320 (70.0)	1172 (77.6)	3378 (72.4)
Veterans Affairs	75 (16.4)	109 (7.2)	117 (2.5)
Critical access	28 (6.1)	134 (8.9)	893 (19.1)
Military	19 (4.2)	46 (3.0)	49 (1.1)
Children's	6 (1.3)	27 (1.8)	81 (1.7)
Women's and children's	4 (0.9)	7 (0.5)	15 (0.3)
Surgical	3 (0.7)	9 (0.6)	111 (2.4)
Oncology	1 (0.2)	3 (0.2)	18 (0.4)
Women's	1 (0.2)	4 (0.3)	6 (0.1)

Potential
SAAR
representation

Current SAAR
representation



SAAR Interpretation

- SAAR = Observed DOT / Predicted DOT
 - SAAR > 1.0 indicates AU higher than predicted
 - SAAR = 1.0 indicates AU equal to predicted
 - SAAR < 1.0 indicates AU lower than predicted
- High or low SAAR does not indicate inappropriate use
 - Signal for exploration

<https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/au-saar-guide-508.pdf>




All antibacterial agents

All antibacterial agents in the AUR protocol **except**: AMIKACIN LIPOSOME , CEFIDEROCOL , COLISTIN , DELAFLOXACIN , ERAVACYCLINE , IMIPENEM/CILATATIN/RELEBACTAM , LEFAMULIN , MEROPENEM/VABORBACTAM , OMADACYCLINE , PIPERACILLIN , PLAZOMICIN , TICARCILLIN/CLAVULANA

All Adult SAAR Locations

All Pediatric SAAR Locations




Preliminary Data. Not intended for distribution



Broad-spectrum antibacterial agents used for community-acquired infections

Adult: CEFACLOR, CEFDINIR, CEFIXIME, CEFOTAXIME, CEFPODOXIME, CEFPROZIL, CEFTRIAXONE, CEFUROXIME, CIPROFLOXACIN, ERTAPENEM, GEMIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN

Pediatric: AMOXICILLIN/CLAVULANATE, AMPICILLIN/SULBACTAM, CEFACLOR, CEFDINIR, CEFIXIME, CEFOTAXIME, CEFPODOXIME, CEFPROZIL, CEFTRIAXONE, CEFUROXIME




Preliminary Data. Not intended for distribution

Broad-spectrum antibacterial agents used for community-acquired infections


Adult: CEFACLOR, CEFDINIR, CEFIXIME, CEFOTAXIME, CEFPODOXIME, CEFPROZIL, CEFTRIAXONE, CEFUROXIME, CIPROFLOXACIN, ERTAPENEM, GEMIFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN

Pediatric: AMOXICILLIN/CLAVULANATE, AMPICILLIN/SULBACTAM, CEFACLOR, CEFDINIR, CEFIXIME, CEFOTAXIME, CEFPODOXIME, CEFPROZIL, CEFTRIAXONE, CEFUROXIME



Antibacterial agents posing highest risk for CDI

Adult and Pediatric: CEF DINIR , CEF EPIME , CEF IXIME , CEF OTAXIME , CEF PODOXIME , CEF TAZIDIME , CEF TRIAXONE , CIPROFLOXACIN , CLINDAMYCIN , GEMIFLOXACIN , LEVOFLOXACIN , MOXIFLOXACIN



Broad-spectrum antibacterial agents used for hospital-onset infections

Adult: AMIKACIN (IV only) , AZTREONAM (IV only) , CEFEPIME , CEFTAZIDIME , DORIPENEM , GENTAMICIN (IV only) , IMIPENEM/CILASTATIN , MEROPENEM , PIPERACILLIN/TAZOBACTAM , TOBRAMYCIN (IV only)


Pediatric: AMIKACIN (IV only) , AZTREONAM (IV only) , CEFEPIME , CEFTAZIDIME , CIPROFLOXACIN , DORIPENEM , ERTAPENEM , GEMIFLOXACIN , IMIPENEM/CILASTATIN , LEVOFLOXACIN , MEROPENEM , MOXIFLOXACIN , PIPERACILLIN/TAZOBACTAM , TOBRAMYCIN (IV only)

Adult ICU

Adult Step

Adult Ward

Pediatric Ward



Preliminary Data. Not intended for distribution

Is seeing data comparing yourself to other hospitals helpful?

Yes

No



Which class of antibiotics are you most likely to look at?

Carbapenems

Fluoroquinolones

Aggregate of community onset antibiotics

Aggregate of hospital onset infection antibiotics

Aggregate of antibiotics contributing to C.diff

Total antibiotic use

Something else



What comparison would be the most impactful to other hospitals of your size?

High Risk C.diff antibiotics

Total antibiotics

Prescribing by patient location (ICU, Ward)

Something else

